LAMC2 promotes gallbladder carcinoma metastasis through the TGF-β pathway Authors: Mengyou Xu, Yuanyuan Zhang, Huibo Feng, Taiyu Shang, Yibin Chen, Erdong Liu, Yunkai Lin, Yufei Pan, Yanan Zhou, Xiaofan Feng, Liwei Dong, Tianyi Jiang, Hongyang Wang Published: 2025 ABSTRACT BackgroundGallbladder cancer (GBC) is an aggressive malignant tumor that seriously threatens the survival of GBC patients. Laminin-γ2 (LAMC2), an important component of laminins, has been reported to facilitate cancer development and chemoresistance in several cancers. However, the biological effect of LAMC2 on GBC is still unclear.MethodsLAMC2 expression was assessed in GBC specimens through proteomics and RNA-seq data. To evaluate the biological effects of LAMC2, we performed colony formation, sphere formation, wound healing, and transwell and invasion assays, along with an in vivo metastasis model. Additionally, we also explored the role of LAMC2 in GBC organoid. Finally, Western blot and RT-qPCR were employed to identify the molecular mechanism underlying LAMC2-mediated regulation of aggressive behavior in GBC.ResultsHere, we revealed that LAMC2 was overexpressed in GBC tissues and was positively correlated with poor patient outcomes. Furthermore, the genetic silencing of LAMC2 significantly inhibited GBC cell colony formation, sphere formation, and organoid growth. Additionally, LAMC2 deficiency impaired GBC cell metastasis in vitro and in vivo, accompanied by a reversal of the epithelial-mesenchymal transition (EMT) phenotype. Mechanistically, LAMC2 expression was induced by the canonical TGF-β/SMAD2 signaling pathway, and in turn, LAMC2 feedback enhanced the activity of TGF-β signaling by binding to TGF-β receptor II (TGF-βRII).ConclusionOur findings suggest that LAMC2 promotes GBC progression and metastasis, potentially by regulating the TGF-β signaling pathway. Therefore, LAMC2 could serve as a potential prognostic biomarker and therapeutic target for GBC.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12935-025-04123-z. Introduction Gallbladder cancer (GBC) is a highly lethal biliary tract cancer with a poor prognosis [1]. Owing to its unique anatomical location and lack of obvious clinical symptoms, most patients are diagnosed at an advanced stage, often with local or distant metastasis [2]. Despite the utilization of various treatment approaches, the 5-year survival rate remains below 5% [3]. Therefore, exploring functional biological biomarkers is imperative to intervene in disease progression. The pivotal involvement of the extracellular matrix (ECM) in oncogenesis has been well-established in numerous studies, making ECM components attractive candidates for targeted therapeutic development [4]. Laminins are important and biologically active ECM protein complexes that involved in many biological processes, including cell differentiation, migration, adhesion, and metastasis [5, 6]. LAMC2, which encodes laminin γ2, along with LAMA3 (encoding α3) and LAMB3 (encoding β3), collectively form the heterotrimeric glycoprotein laminin-332 (LM 332) [7]. As the unique subunit of LM 332, LAMC2 is emerging as a potential therapeutic target [8]. LAMC2 not only localizes to the cytoplasm, where it is implicated in tumor invasion and metastasis, but is also secreted, making it a detectable circulating diagnostic biomarker [9, 10]. LAMC2 has been implicated in the activation of multiple oncogenic signaling pathways. A study found LAMC2 expression was elevated in anaplastic thyroid carcinoma and showed LAMC2 could interact with EGFR, thereby inducing the activation of AKT and ERK1/2 activation [11]. Although the upregulation of the LAMC2 gene has been detected in multiple tumors, such as esophageal squamous cell carcinoma [12], breast cancer [13], cholangiocarcinoma [14], and pancreatic adenocarcinoma [15], its functional significance in GBC carcinogenesis remains enigmatic. Therefore, our study systematically characterized the biological effect of LAMC2 on GBC and the underlying molecular mechanism involved. LAMC2 promoted the malignant phenotypes of GBC tumor cells, including enhanced proliferation, migration, and invasion. We also established a functional link between TGF-β signaling and LAMC2. The potential mechanisms involve the transcriptional upregulation of LAMC2 by SMAD2, as well as the interaction between LAMC2 and TGF-βRII, which further strengthens the TGF-β pathway and induces the expression of downstream EMT-related molecules. Our findings identify the LAMC2-TGF-β/SMAD2 axis as an important driver in GBC metastasis, suggesting its potential for therapeutic intervention. Materials and methods 1. Patients Fresh surgical and paraffin-embedded specimens of GBC and normal gallbladder (GB) were obtained from the Eastern Hepatobiliary Surgery Hospital (EHBH), Naval Military Medical University (Shanghai). All cases underwent pathological confirmation and were collected with ethical approval (EHBH Research Ethics Committee). Informed consents were obtained from all patients. 2. Organoid isolation and culture Fresh tissue samples were collected and digested using a cocktail containing collagenase D (4 mg/ml, Roche), DNase I (0.1 mg/ml, Sigma), Y27632 (2 µM, Sigma-Aldrich), and Primocin (100 µg/ml, InvivoGen) in DMEM (BasalMedia) at 37 °C for 30–50 min. The resulting suspension was filtered using a cell strainer (100 μm). The cell pellets were embedded in Matrigel (BD Transduction Laboratories, USA), mixed with suspension medium, and allowed to solidify in a 6-well suspension culture plate in a cell culture incubator for 30 min. Each well was filled with appropriate culture medium after gelation. The organoid culture medium consisted of advanced DMEM/F12 supplemented with 1% penicillin/streptomycin, 1% GlutaMAX-I, 10 mM HEPES, 100 µg/ml Primocin, 2% B27 supplement (without vitamin A), 1.25 mM N‐acetyl‐l‐cysteine, 50 ng/ml mouse recombinant EGF, 10 µM Y27632, 5 µM A8301, 100 ng/ml recombinant human FGF10, 1 ng/ml recombinant human FGF‐basic, 10 µM forskolin, 25 ng/ml recombinant human HGF, 5% Noggin conditioned media, 2% Rspo-1 conditioned medium, and 15% Wnt3a‐conditioned medium. LAMC2 knockdown was performed directly in our established GBC patient-derived organoids. Specifically, mature organoids were harvested and dissociated into single cells. The single-cell suspension was then infected with LAMC2-targeting lentivirus. The infected cells were resuspended in organoid culture medium and seeded into a 48-well plate. To enhance infection efficiency, the plate was centrifuged for 1 h to promote cell-virus contact, followed by a 1-hour incubation in a cell culture incubator. After this incubation period, the cells were carefully embedded in Matrigel to allow for the reformation and growth of organoids. For the organoid growth analysis, LAMC2-depleted and control organoids were trypsinized into single cells and seeded with an equal number of cells in Matrigel. The organoids were then cultured in organoid medium to allow the formation of organoid structures. Multiple fields were imaged, and the total organoid area in each field was calculated using ImageJ. The average area per organoid in each field was calculated by dividing the total area by the number of organoids to assess growth differences. 3. Proteomic mass spectrometry analysis Protein samples subjected to mass spectrometry were derived from 10 GB and 17 GBC fresh specimens. Samples were pooled within each group and analyzed collectively as one sample per group. Given that cell membrane proteins play diverse functional roles and are highly targetable in tumors, we performed mass spectrometry analysis to profile the membrane proteome. Membrane proteins were prepared following a differential centrifugation-based method [16, 17]. Briefly, tissues were homogenized in ice-cold hypotonic buffer, and the postnuclear supernatant was subjected to ultracentrifugation to obtain the crude membrane pellet, which was subsequently solubilized for LC-MS/MS analysis. Protein abundances were estimated using the emPAI value provided by Mascot 2.5 in Proteome Discoverer. These values were then normalized across samples based on the total quantifiable protein abundance in each run. The proteins with a normalized abundance ratio (GBC/GB) ≥ 2.0 or ≤ 0.5 were considered differentially expressed. 4. RNA-seq RNA sequencing procedure and data analysis were performed by LC-Bio Technologies (Hangzhou) Co., Ltd. The analysis was performed on 24 GBC samples compared with 6 GB tissues. Raw read counts were normalized and differential expression analysis was conducted using the DESeq2 R package. The differentially expressed genes (|log2 fold change (FC)| ≥ 1, p-value < 0.05) were determined as statistically significant. 5. Immunohistochemistry staining GBC specimens were fixed in 4% paraformaldehyde for IHC analysis. IHC staining was operated by fully automated staining systems (BOND-MAX) under the antigen-antibody reaction and chemical reactions procedure. Microscopic evaluation was systematically performed by examining at least five 200x fields per section. Immunoreactivity score (IRS) was determined by multiplying staining intensity (SI) scores (0: negative; 1: weak; 2: moderate; 3: strong) with percentage of positive cells (PP) scores (0: 0%; 1: 0–25%; 2: 25–50%; 3: 50–75%; 4: 75–100%). All patients were stratified into high (IRS > 5) and low (IRS ≤ 4) expression groups based on the median IRS thresholds. 6. RNA extraction and quantitative real-time PCR (RT-qPCR) Total RNA was isolated via TRIzol reagent (Invitrogen) and quantified with Nanodrop 1000 (Thermo Fisher Scientific). 1000 ng were reverse transcribed to cDNA using the reverse transcription kit (Vazyme kit). RT-qPCR was conducted with 2x Taq Pro Universal SYBR Green mix (Vazyme) under LightCycler 480. The primer sequences are detailed in Additional file 1: Table S1. 7. Western blotting analysis GBC cells were washed with PBS and lysed in ice using RIPA (Beyotime) mixed with protease and phosphatase inhibitors (TargetMol). Protein concentrations were quantified using BCA assay (ThermoFisher), with 20–50 ug lysates loaded in SDS-PAGE gels and then transferred onto nitrocellulose membrane (NC, Cytiva). After 1 h of blocking in 5% BSA, membranes were sequentially incubated with primary antibodies and fluorescein-conjugated secondary antibodies. The results were performed under Odyssey fluorescence scanner (LI-COR). The antibodies used are listed below: anti-LAMC2 (Abcam, Ab210959), anti-E-cadherin (Protein technology, 20874-1−1AP), anti-GAPDH (Abclonal, AC002), anti-SMAD2 (Protein technology, 12750-1−1AP), anti-β-actin (Protein technology, 66009-1-Ig), anti-p-SMAD2/3 (Cell Signaling, 8828 T), and SMAD2/3 (Selleck, M18H19). 8. Cell lines and culture conditions Human gallbladder cancer cell lines GBC-SD were obtained from Shanghai Cell Bank of the Chinese Academy of Sciences, China. NOZ cell line was purchased from RIKEN cell bank, Japan. Human primary GBC cell lines HCC453 and HCC668 were derived from male patients in the Eastern Hepatobiliary Surgery Hospital (EHBH) and established by our group. GBC-SD was cultured in Dulbecco’s modified Eagle medium (DMEM, BasalMedia), and HCC453 was in RPMI 1640 medium (BasalMedia), with 10% fetal bovine serum (FBS, BI), penicillin (100 IU/ml; Gibco) and streptomycin (100 µg/ml; Gibco). All the cells were cultured in a humidified atmosphere at 37 °C with 5% CO2. For activating or inhibiting TGF-β signaling, GBC cell lines were stimulating with TGF-β1 (Peprotech, 20 ng/ml) or vactosertib (MCE, 1 µM), respectively. 9. Cell transfection The lentivirus vectors used to knock down or overexpress LAMC2 were purchased from Genechem Co.,Ltd (Shanghai, China). For lentivirus infection, cells were transduced with the virus solution using transfection reagent (HiTransG A) and subsequently selected with 2 µg/ml puromycin. LAMC2 expression levels were assessed by western blot and RT-qPCR. Small interfering RNA (siRNA) for knocking down SMAD2 was synthesized from Generay Biotechnology (Shanghai, China). siRNA mixed transfection reagent lipo8000 (Beyotime) was added to the medium. After 24 h, the supernatant was replaced with fresh medium and treated with TGF-β1. The sequences for the shRNA targeting LAMC2 and siSMAD2 were listed as follows: shLAMC2: forward, 5’-GGCAGGUGUUUGAAGUGUAUC-3’; reverse, 5’-UACACUUCAAACACCUGCCUG-3’; siSMAD2: forward, 5’-GCUUCUCUGAACAAACCAGTT-3’; reverse, 5’-CUGGUUUGUUCAGAGAAGCTG-3’. 10. Colony formation For colony formation, GBC-SD/HCC453 cells were seeded at 3 × 103 cells/well in 6-well plates. Following 14 days of incubation, the cell colonies were first fixed using 4% paraformaldehyde for 15 min, followed by 15-minute crystal violet staining. The plates were washed twice with PBS and then photographed using a camera. Colony numbers were counted. The numbers were normalized to those of the control group and presented as relative values. 11. Sphere formation assay For sphere formation assay, 9000 cells per well were cultured for 10 days in 2 ml serum-free medium (DMEM/F12 with 1% B27, 20 ng/ml EGF, and 10 ng/ml bFGF) using ultra-low attachment 6-well plates. The spheres were visualized and photographed under an inverted microscope. 12. Transwell and invasion assay For migration and invasion analysis, 2 × 104 cells in a 200 µl serum-free medium were placed into the upper chamber, while the lower chamber contained 10% serum medium (500 µl/well). After 48 h incubation, the cells were subjected to 4% paraformaldehyde for 15 min and stained using crystal violet solution for 15 min. The number of penetrating cells was quantified under a microscope (Olympus) after the removal of upper chamber cells with the cotton swab. 13. Wound healing assay GBC-SD/HCC453 cells were cultured into 6-well plates. Until reaching over 95% fusion, cells were scratched by a 10 µl sterile pipette. Images were taken to evaluate the change in the width of the wound using the microscope (Olympus). 14. Co‑immunoprecipitation (co‑IP) Protein lysates were prepared from plasmid-transfected 293 T cells via RIPA. The lysates were subjected to immunoprecipitation by overnight incubation at 4 °C with the indicated antibodies and Protein A/G Agarose Beads (Beyotime). After incubation, the beads were then resuspended in loading buffer and boiled to collect the bound proteins followed by western blot analysis. The LAMC2-Flag and TGF-βRII-Myc plasmids used in the experiments were purchased from Miaoling Bio. The antibodies used are listed below: anti-Myc tag (Protein technology, 60003-2-Ig). 15. Immunofluorescence (IF) analysis The cells were first fixed with 4% paraformaldehyde. Subsequently, permeabilization was carried out using 0.2% Triton X-100. The cells were then blocked with 10% goat serum and incubated with primary antibodies overnight. Following staining with a fluorescent secondary antibody and Hoechst (Sigma) for nuclei, image were acquired on a confocal microscope. Anti-Myc tag (Protein technology, 60003-2-Ig) and anti-Flag tag (Protein technology, 66008-4-Ig) were used in this experiment. 16. CUT&Tag analysis CUT&Tag (Cleavage Under Targets and Tagmentation) was performed based on the manufacturer’s protocol (Vazyme CUT&Tag Assay Kit). Briefly, cells were washed and bound to ConA beads in Binding Buffer. After incubation with a primary antibody against SMAD2 overnight at 4 °C and a secondary antibody for 1 h at room temperature, the samples were incubated with Hyperactive pA/G-Tnp (pA/G-Tn5 transposase) for 1 h. Tagmentation was carried out at 37 °C for 1 h in TTBL buffer, followed by termination with 10% SDS and DNA Spike-in. DNA was extracted using DNA Extract Beads, and libraries were constructed by adapter ligation and PCR amplification. Final libraries were purified with VAHTS DNA Clean Beads and eluted for high-throughput sequencing. 17. Liver metastatic analysis using mouse model The BALB/c nude mice (6 weeks old, males) were acquired from GemPharmatech (Jiangsu, China). All mice were supplied with specific pathogen-free (SPF) housing. To establish a liver metastasis model, 5 × 105 GBC-SD cells transduced with either shControl or shLAMC2 were intrasplenically injected into nude mice with subsequent splenectomy. After 2 months, liver metastases were collected for quantification and pathological analysis. 18. Statistical analysis The statistical analysis was performed by GraphPad Prism software 9. Data were presented as mean ± standard deviations (SD). Unpaired two-tailed Student’s t-test or Mann-Whitney U test was used for two groups comparison. For multiple groups comparison, a one-way ANOVA was performed with post hoc testing. Survival outcomes in the human GBC cohort were analyzed through Kaplan-Meier method with log-rank testing. Univariate and multivariate Cox regression analyses were conducted to determine the independent factors on survival. The correlation between the LAMC2 expression and clinicopathological characters was examined using χ² tests. The statistical significance threshold is set at p < 0.05, while “ns” means no significance. Results 1. LAMC2 is specifically overexpressed in GBC by proteomic and RNA-seq assays To identify specific membrane molecular markers for GBC, we conducted proteomic mass spectrometry analysis of the cell membrane proteome. An analysis of the mass spectra revealed significant differential protein expression in GBC versus normal gallbladder (GB) tissues, revealing 624 proteins with increased level (FC ≥ 2) and 132 proteins with decreased levels (FC ≤ 0.5). We further focused on the proteins with increased levels closely related to tumor progression that are easily targeted. Moreover, RNA-seq analysis revealed that 270 genes were upregulated, and 20 overlapping genes were identified in both the proteomic and RNA-seq data (Fig. 1A-C). To verify the expression of these genes, real-time qPCR (RT-qPCR) and western blot (WB) assays were performed in the GBC and GB tissues. In addition to low-abundance proteins, RT-qPCR revealed that LAMC2 was significantly elevated in GBC tissues, whereas the expression of other genes did not significantly differ (Fig. 1D, E). Consistent with the mRNA results, GBC tissues presented much higher LAMC2 protein levels than GB tissues did (Fig. 1F). Analysis of the published dataset (GSE202479) confirmed that LAMC2 was significantly upregulated in advanced GBC tissues compared with normal GB, but no obvious differences were observed between early-stage GBC, intracholecystic papillary neoplasm (IPCN) and cholecystisis (GBS) (Fig. 1G). Furthermore, we found that LAMC2 was upregulated in most cancers compared with the corresponding normal tissues from the TCGA database (Fig. 1H). Together, these findings highlight that LAMC2 is aberrantly upregulated and may display important roles in promoting tumor progression. Fig. 1LAMC2 is significantly overexpressed in GBC. (A) The Venn diagram of upregulated genes through the proteomic analysis (17 GBC and 10 GB samples) and RNA-seq (24 GBC and 6 GB samples) in GBC compared with GB. (B) The table of 20 overlapping upregulated proteins with normalized abundance and fold change (FC) values in GBC and GB according to proteomic analysis. (C) The volcano plot of gene expression from RNA-seq data. (D) The heatmap of relative expression of selected upregulated genes in GBC (n = 21) compared with GB (n = 13). (E) LAMC2 mRNA expression in GBC (n = 21) versus GB (n = 13). (F) The protein level of LAMC2 in GBC (n = 6) and GB (n = 6) was determined via western blot (WB) assay. (G) The LAMC2 expression in cholecystitis (GBS, n = 4), intracholecystic papillary neoplasm (ICPN, n = 3), early GBC (n = 5), and advanced GBC (n = 5) versus GB (n = 3) from the GSE202479 dataset. (H) The LAMC2 expression in pan-cancer from TCGA database. The Mann-Whitney U test was calculated for statistical significance (E and H) and one-way ANOVA was employed for the data of Fig. 1G. Values are expressed as mean ± SD. * p < 0.05 LAMC2 is significantly overexpressed in GBC. (A) The Venn diagram of upregulated genes through the proteomic analysis (17 GBC and 10 GB samples) and RNA-seq (24 GBC and 6 GB samples) in GBC compared with GB. (B) The table of 20 overlapping upregulated proteins with normalized abundance and fold change (FC) values in GBC and GB according to proteomic analysis. (C) The volcano plot of gene expression from RNA-seq data. (D) The heatmap of relative expression of selected upregulated genes in GBC (n = 21) compared with GB (n = 13). (E) LAMC2 mRNA expression in GBC (n = 21) versus GB (n = 13). (F) The protein level of LAMC2 in GBC (n = 6) and GB (n = 6) was determined via western blot (WB) assay. (G) The LAMC2 expression in cholecystitis (GBS, n = 4), intracholecystic papillary neoplasm (ICPN, n = 3), early GBC (n = 5), and advanced GBC (n = 5) versus GB (n = 3) from the GSE202479 dataset. (H) The LAMC2 expression in pan-cancer from TCGA database. The Mann-Whitney U test was calculated for statistical significance (E and H) and one-way ANOVA was employed for the data of Fig. 1G. Values are expressed as mean ± SD. * p < 0.05 2. Upregulation of LAMC2 is correlated with poorer prognosis in GBC To assess the relevance between LAMC2 expression and prognosis in GBC patients, LAMC2 expression was detected in GBC and GB tissues by immunohistochemistry (IHC) staining. We found that LAMC2 was strongly expressed in GBC but weakly expressed in GB tissues (Fig. 2A). We then analyzed a cohort containing 153 cases of GBC based on IHC staining (Fig. 2B). Survival stratification by LAMC2 expression demonstrated markedly reduced overall survival (OS) in GBC patients with high expression of LAMC2 (Fig. 2C). Elevated LAMC2 expression levels were correlated with advanced TNM stage (Table 1). Furthermore, LAMC2 was an independent risk determinant influencing GBC survival via univariate and multivariate Cox regression analyses (Fig. 2D; Table 2). Additionally, this association extended to other malignancies, including pancreatic adenocarcinoma (PAAD), lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), and head and neck squamous cell carcinoma (HNSC) from TCGA database (Fig. 2E). These results suggest that LAMC2 expression is enhanced in GBC and plays a crucial role in GBC progression. Fig. 2Upregulation of LAMC2 is correlated with poorer prognosis in GBC. A. IHC staining of LAMC2 expression in GB (n = 3) and GBC samples (n = 3). F. The representative images of LAMC2 staining intensity in GBC. C. Kaplan-Meier analysis of different LAMC2 expression levels in the GBC cohort (n = 153). D. The forest diagram of the multivariate regression analysis for GBC patients. E. The survival curves of PAAD, LUSC, LUAD, and HNSC patients according to LAMC2 expression level from the TCGA database. * p < 0.05, **p < 0.01, ***p < 0.001 Upregulation of LAMC2 is correlated with poorer prognosis in GBC. A. IHC staining of LAMC2 expression in GB (n = 3) and GBC samples (n = 3). F. The representative images of LAMC2 staining intensity in GBC. C. Kaplan-Meier analysis of different LAMC2 expression levels in the GBC cohort (n = 153). D. The forest diagram of the multivariate regression analysis for GBC patients. E. The survival curves of PAAD, LUSC, LUAD, and HNSC patients according to LAMC2 expression level from the TCGA database. * p < 0.05, **p < 0.01, ***p < 0.001 Table 1Correlation of LAMC2 expression with the clinicopathological features of GBCLAMC2 (low)LAMC2 (high)p-valueN = 85%N = 68%Sexual0.418 Male5334.64730.7 Female3220.92113.7Age0.352 > 653522.92315 ≤ 655032.74529.4Differential grade0.847 Poor149.2127.8 Well/moderate7146.45636.6LNM0.241 N06743.84831.4 N1-21811.82013.1TNM stage0.028* I-II159.842.6 III-IV7045.86441.8χ² test was performedp < 0.05 was considered statistically significant, * p < 0.05 Table 1Correlation of LAMC2 expression with the clinicopathological features of GBCLAMC2 (low)LAMC2 (high)p-valueN = 85%N = 68%Sexual0.418 Male5334.64730.7 Female3220.92113.7Age0.352 > 653522.92315 ≤ 655032.74529.4Differential grade0.847 Poor149.2127.8 Well/moderate7146.45636.6LNM0.241 N06743.84831.4 N1-21811.82013.1TNM stage0.028* I-II159.842.6 III-IV7045.86441.8χ² test was performedp < 0.05 was considered statistically significant, * p < 0.05 Correlation of LAMC2 expression with the clinicopathological features of GBC χ² test was performed p < 0.05 was considered statistically significant, * p < 0.05 Table 2Univariate and multivariate Cox regression analyses of LAMC2 expression for GBC patients OS (n = 153)VariableUnivariate analysisMultivariate analysisHR95%CIP valueHR95%CIP valueAge ≤65 vs. >651.0320.634–1.6820.899Gender Female vs. male0.9580.588–1.560.863Stone Presence vs. absence1.3740.853–2.2130.191Jaundice Presence vs. absence1.3550.831–2.2070.223Tumor location Peritoneal side vs. hepatic0.850.532–1.3580.497Resection R1 vs. R00.6040.309–1.1790.14Extrahepatic bile duct resection Yes vs. No1.2570.78–2.0250.348Differentiation grade Well/moderate vs. poor0.5470.313–0.9560.034*0.5010.281–0.8930.019*PathologyNon- adenocarcinoma vs. adenocarcinoma1.9610.895–4.2990.0922.1280.943–4.8050.069LNM N1-2 vs. N03.6212.156–6.083< 0.001*3.4682.027–5.933< 0.001*TNM staging system III&IV vs. I&II2.6841.153–6.2470.022*1.6780.673–4.1820.267LAMC2 immunoreactivity High vs. low2.281.408–3.692< 0.001*2.2331.36–3.6650.001*HR hazard ratio; CI confidence intervalp < 0.05 was considered statistically significant, * p < 0.05 Table 2Univariate and multivariate Cox regression analyses of LAMC2 expression for GBC patients OS (n = 153)VariableUnivariate analysisMultivariate analysisHR95%CIP valueHR95%CIP valueAge ≤65 vs. >651.0320.634–1.6820.899Gender Female vs. male0.9580.588–1.560.863Stone Presence vs. absence1.3740.853–2.2130.191Jaundice Presence vs. absence1.3550.831–2.2070.223Tumor location Peritoneal side vs. hepatic0.850.532–1.3580.497Resection R1 vs. R00.6040.309–1.1790.14Extrahepatic bile duct resection Yes vs. No1.2570.78–2.0250.348Differentiation grade Well/moderate vs. poor0.5470.313–0.9560.034*0.5010.281–0.8930.019*PathologyNon- adenocarcinoma vs. adenocarcinoma1.9610.895–4.2990.0922.1280.943–4.8050.069LNM N1-2 vs. N03.6212.156–6.083< 0.001*3.4682.027–5.933< 0.001*TNM staging system III&IV vs. I&II2.6841.153–6.2470.022*1.6780.673–4.1820.267LAMC2 immunoreactivity High vs. low2.281.408–3.692< 0.001*2.2331.36–3.6650.001*HR hazard ratio; CI confidence intervalp < 0.05 was considered statistically significant, * p < 0.05 Univariate and multivariate Cox regression analyses of LAMC2 expression for GBC patients OS (n = 153) Age ≤65 vs. >65 Gender Female vs. male Stone Presence vs. absence Jaundice Presence vs. absence Tumor location Peritoneal side vs. hepatic Resection R1 vs. R0 Differentiation grade Well/moderate vs. poor Pathology Non- adenocarcinoma vs. adenocarcinoma LNM N1-2 vs. N0 TNM staging system III&IV vs. I&II LAMC2 immunoreactivity High vs. low HR hazard ratio; CI confidence interval p < 0.05 was considered statistically significant, * p < 0.05 3. LAMC2 regulates GBC cell growth and stemness characteristics We next sought to delineate the biological functions of LAMC2 in GBC. Among the evaluated GBC cell lines, GBC-SD and HCC453 exhibited abundant LAMC2 expression (Fig. 3A). To explore the functional role of LAMC2, we stably knocked down LAMC2 expression in GBC-SD and HCC453 cells with lentiviral vectors expressing LAMC2-specific shRNAs. LAMC2 expression was significantly reduced after transduction with the shLAMC2 lentiviral vector, as confirmed by WB and RT-qPCR (Fig. 3B, C). To ask about the impact of LAMC2 on cell growth, we first examined its effects on colony formation. Knockdown of LAMC2 notably suppressed the colony formation in GBC-SD and HCC453 cells (Fig. 3D). The subsequent sphere formation assay further demonstrated that LAMC2 silencing diminished the sphere formation in GBC-SD cells (Fig. 3E). At the same time, our data showed that the expression of these stemness markers, including SOX2, NANOG and CD44 was downregulated upon LAMC2 depletion as assessed by qPCR, consistent with impaired stem-like properties (Fig. 3F). Additionally, we knocked down LAMC2 in GBC organoids from human GBC specimens (Fig. 3G). In the sphere propagation phase, there was a significant reduction in the organoid sphere area upon LAMC2 knockdown relative to that of the control organoids (Fig. 3H). These findings underscore that LAMC2 is involved in GBC malignancy by regulating cell growth and stemness. Fig. 3LAMC2 regulates GBC cell growth and stemness characteristics. (A) The protein expression levels in GBC cell lines. (B) The protein level of LAMC2 expression in the shControl and shLAMC2 groups. (C) The mRNA level of LAMC2 expression in the shControl and shLAMC2 groups. (D) The representative images of colony formation and relative colony numbers of shControl- and shLAMC2-treated GBC-SD and HCC453 cells. (E) The representative images of sphere formation in GBC-SD cells after LAMC2 silencing. Scare bars = 200 μm. (F) The mRNA levels of stemness markers NANOG, SOX2 and CD44 in spheres upon LAMC2 knockdown. (G) The protein level of LAMC2 after lentivirus infection in GBC organoid. (H) The representative images of organoids after LAMC2 knockdown and quantification of the mean area per organoid. Scare bars = 200 μm. Unpaired Student’s t- test was calculated for statistical significance. Values are expressed as mean ± SD. * p < 0.05, **p < 0.01, ***p < 0.001. n = 3 independent biological samples LAMC2 regulates GBC cell growth and stemness characteristics. (A) The protein expression levels in GBC cell lines. (B) The protein level of LAMC2 expression in the shControl and shLAMC2 groups. (C) The mRNA level of LAMC2 expression in the shControl and shLAMC2 groups. (D) The representative images of colony formation and relative colony numbers of shControl- and shLAMC2-treated GBC-SD and HCC453 cells. (E) The representative images of sphere formation in GBC-SD cells after LAMC2 silencing. Scare bars = 200 μm. (F) The mRNA levels of stemness markers NANOG, SOX2 and CD44 in spheres upon LAMC2 knockdown. (G) The protein level of LAMC2 after lentivirus infection in GBC organoid. (H) The representative images of organoids after LAMC2 knockdown and quantification of the mean area per organoid. Scare bars = 200 μm. Unpaired Student’s t- test was calculated for statistical significance. Values are expressed as mean ± SD. * p < 0.05, **p < 0.01, ***p < 0.001. n = 3 independent biological samples 4. LAMC2 promotes GBC cell migration and invasion both in vitro and in vivo To further investigate the functional role of LAMC2 in GBC progression, we conducted transwell assays and wound healing. We found that LAMC2 knockdown notably decreased the migration and invasive capabilities of GBC cells (Fig. 4A-B). Similarly, wound healing assays also showed that LAMC2 deficiency inhibited GBC cell migration (Fig. 4C-D). Moreover, we overexpressed LAMC2 in GBC-SD cells using lentivirus (Fig. 4E). The migration and invasion capacity of GBC-SD cells was significantly potentiated by ectopic LAMC2 expression (Fig. 4F). To validate the above results in vivo, nude mice received intrasplenic injection of shLAMC2 or shControl GBC-SD cells for subsequent evaluation of hepatic dissemination. The liver metastatic burden was lower in the shLAMC2 group than in the shControl group (Fig. 4G). Collectively, these findings suggest that LAMC2 plays a crucial role in promoting GBC metastasis. Fig. 4LAMC2 promotes GBC cell migration and invasion in vitro and in vivo. A-B. The representative images of transwell and invasion assays and relative cell numbers in GBC-SD (A) and HCC453 (B) cells. C-D. The representative images of wound healing assays and rates of wound closure in GBC-SD (C) and HCC453 (D) cells. E. LAMC2 protein and mRNA levels in GBC-SD cells subjected to lentiviral transduction. F. The representative images of transwell and invasion assays in LAMC2-overexpressing GBC-SD cells. Scare bars = 200 μm. G. The representative images of gross images, H&E images, and numbers of liver metastatic nodules from shControl and shLAMC2 of GBC-SD in the orthotopic liver model of metastasis. Scare bars = 500 μm. Unpaired Student’s t- test was calculated for statistical significance. Values are expressed as mean ± SD. * p < 0.05, **p < 0.01, ***p < 0.001. n = 3 biologically independent samples LAMC2 promotes GBC cell migration and invasion in vitro and in vivo. A-B. The representative images of transwell and invasion assays and relative cell numbers in GBC-SD (A) and HCC453 (B) cells. C-D. The representative images of wound healing assays and rates of wound closure in GBC-SD (C) and HCC453 (D) cells. E. LAMC2 protein and mRNA levels in GBC-SD cells subjected to lentiviral transduction. F. The representative images of transwell and invasion assays in LAMC2-overexpressing GBC-SD cells. Scare bars = 200 μm. G. The representative images of gross images, H&E images, and numbers of liver metastatic nodules from shControl and shLAMC2 of GBC-SD in the orthotopic liver model of metastasis. Scare bars = 500 μm. Unpaired Student’s t- test was calculated for statistical significance. Values are expressed as mean ± SD. * p < 0.05, **p < 0.01, ***p < 0.001. n = 3 biologically independent samples 5. LAMC2 influences GBC metastasis through the TGF-β pathway Epithelial-to-mesenchymal transition (EMT) has been mechanistically linked to metastatic dissemination [18]. Given that previous results indicated that LAMC2 regulated the migration and invasion ability of GBC cells, we speculated that LAMC2 may promote metastasis via EMT. To explore this hypothesis, the EMT marker E-cadherin was detected in GBC cells with differential expression of LAMC2. Notably, LAMC2 knockdown increased E-cadherin expression, while overexpression of LAMC2 markedly reduced it (Fig. 5A), consistent with the known loss of E-cadherin is a hallmark of EMT. We next examined the effect of LAMC2 expression on TGF-β signaling activation and downstream EMT targets following TGF-β1 stimulation. Knockdown of LAMC2 reduced SMAD2/3 phosphorylation (Fig. 5B), while its overexpression further enhanced the phosphorylated SMAD2/3 levels induced by TGF-β1 in GBC-SD cells (Fig. 5C). In addition, LAMC2 knockout did not alter cellular TGF-β1 levels, indicating that its regulatory role is mediated through modulating TGF-β signaling activity rather than ligand expression (Fig. 5D). We also found that LAMC2 knockdown reversed the downregulation of E-cadherin in response to TGF-β1 treatment (Fig. 5E). Other EMT markers were also measured through qPCR. The upregulation of mesenchyme markers like N-cadherin and transcription factor ZEB1, ZEB2 and SNAIL induced TGF-β1 were partially inhibited after LAMC2 knockdown (Fig. 5E). Consistently, LAMC2 overexpression enhanced the levels of EMT markers at the protein and mRNA levels following TGF-β1 treatment (Fig. 5F). We further investigated the effect of TGF-β pathway in the promotion of GBC cells migration and invasion by LAMC2. Using the TGF-β receptor antagonist vactosertib, we observed that blockade of TGF-β signaling markedly diminished the enhanced cell migration and invasion capabilities in GBC-SD cells overexpressing LAMC2 (Fig. 5G). This indicates that LAMC2 promotes GBC cell migration and invasion in a TGF-β pathway-dependent manner. To explore the underlying molecular mechanism, we examined whether LAMC2 interacts with key components of the TGF-β receptor complex via co-immunoprecipitation (co-IP). Co-IP experiments demonstrated that LAMC2 specifically interacts with TGF-βRII (Fig. 5H). Additionally, immunofluorescence (IF) staining in GBC-SD cells revealed co-localization of exogenous LAMC2 (Flag-tagged) and TGF-βRII (Myc-tagged) at the cellular membrane and cytoplasm (Fig. 5I). These data collectively indicate that LAMC2 directly binds to TGF-βRII, thereby enhancing TGF-β signaling activation and promote cancer cell migration and invasion. Fig. 5LAMC2 influences GBC metastasis through the TGF-β pathway (A) The expression of E-cadherin in LAMC2-knockdown GBC-SD cells and LAMC2-overexpression GBC-SD cells. (B) The expression level of phosphorylated and total SMAD2/3 in LAMC2-knockdown GBC-SD cells under TGF-β1 (20 ng/ml). (C) The expression level of phosphorylated and total SMAD2/3 in LAMC2-overexpression GBC-SD cells under TGF-β1 (20 ng/ml). (D) The mRNA level of TGF-β1 in LAMC2-knockdown GBC-SD cells and LAMC2-overexpression GBC-SD cells. (E-F). The protein level of E-cadherin and LAMC2 by WB, and the mRNA levels of downstream targets of the TGF-β pathway after LAMC2 knockdown (E) or LAMC2 overexpression under TGF-β1 (20 ng/ml) stimulation. G. The representative images and quantification analysis of transwell assays in LAMC2-overexpressing GBC-SD cells with TGF-βR inhibitor vactosertib (1 µM). H. The interaction between LAMC2 and TGF-βRII was assessed by co-immunoprecipitation with an anti-Myc antibody and immunoblotting with the indicated antibodies in 293 T cells. I. The localization of exogenous LAMC2 (Flag-tagged) and TGF-βRII (Myc-tagged) in GBC-SD cells through immunofluorescence (IF) analysis. One-way ANOVA was calculated for statistical significance. Values are expressed as mean ± SD. * p < 0.05, **p < 0.01, ***p < 0.001, ns means not significant LAMC2 influences GBC metastasis through the TGF-β pathway (A) The expression of E-cadherin in LAMC2-knockdown GBC-SD cells and LAMC2-overexpression GBC-SD cells. (B) The expression level of phosphorylated and total SMAD2/3 in LAMC2-knockdown GBC-SD cells under TGF-β1 (20 ng/ml). (C) The expression level of phosphorylated and total SMAD2/3 in LAMC2-overexpression GBC-SD cells under TGF-β1 (20 ng/ml). (D) The mRNA level of TGF-β1 in LAMC2-knockdown GBC-SD cells and LAMC2-overexpression GBC-SD cells. (E-F). The protein level of E-cadherin and LAMC2 by WB, and the mRNA levels of downstream targets of the TGF-β pathway after LAMC2 knockdown (E) or LAMC2 overexpression under TGF-β1 (20 ng/ml) stimulation. G. The representative images and quantification analysis of transwell assays in LAMC2-overexpressing GBC-SD cells with TGF-βR inhibitor vactosertib (1 µM). H. The interaction between LAMC2 and TGF-βRII was assessed by co-immunoprecipitation with an anti-Myc antibody and immunoblotting with the indicated antibodies in 293 T cells. I. The localization of exogenous LAMC2 (Flag-tagged) and TGF-βRII (Myc-tagged) in GBC-SD cells through immunofluorescence (IF) analysis. One-way ANOVA was calculated for statistical significance. Values are expressed as mean ± SD. * p < 0.05, **p < 0.01, ***p < 0.001, ns means not significant 6. TGF-β regulates expression of LAMC2 via SMAD2 In our previous studies, we found that TGF-β could induce the expression of LAMC2 (Fig. 5D-E). Therefore, we further investigated the specific mechanisms by which TGF-β regulates LAMC2 expression. The data revealed that in response to TGF-β1 treatment, the expression of LAMC2 was upregulated in a time-dependent manner at both the mRNA and protein levels (Fig. 6A-B). Further investigation showed that LAMC2 mRNA expression was inhibited when exposed to the transcription inhibitor actinomycin D (Fig. 6C). These findings indicate that TGF-β1 regulates LAMC2 expression at the transcriptional level. Meanwhile, when we inhibited the TGF-β signaling pathway with the TGF-βR inhibitor vactosertib, the TGF-β1-induced upregulation of LAMC2 expression was significantly attenuated (Fig. 6D). We then employed siRNA to interfere with the components of TGF-β signaling pathway and found that the knockdown of SMAD2 effectively counteracted the TGF-β1-induced upregulation of LAMC2 (Fig. 6E). Therefore, we speculate that SMAD2 may regulate the transcription of LAMC2 expression as a transcription factor. CUT&Tag analysis further revealed that SMAD2 occupancy peaks overlap with the transcriptionally activated regions of LAMC2 and were enhanced upon TGF-β1 treatment (Fig. 6F). Our results indicated that the activation of TGF-β signaling enhanced LAMC2 expression at transcriptional level through SMAD2. In summary, our data indicates that LAMC2 expression is transcriptionally regulated by TGF-β/SMAD2 signaling pathway and plays a critical positive feedback regulatory role in the TGF-β pathway to promote EMT in GBC cells (Fig. 6G). Fig. 6TGF-β regulates expression of LAMC2 via SMAD2. (A) The protein level of LAMC2 under TGF-β1 (20 ng/ml) stimulation in HCC453 and GBC-SD cells. (B) The mRNA level of LAMC2 under TGF-β1(20 ng/ml) stimulation in HCC453 and GBC-SD. (C) The expression of LAMC2 under TGF-β1 stimulation in response to treatment with actinomycin D (1 µM) by qRT-PCR. (D) The protein level of LAMC2 under TGF-β1 stimulation with TGF-β inhibitor vactosertib (1 µM). (E) The protein level of LAMC2 under TGF-β1 stimulation with SMAD2 knockdown in GBC-SD. (F) The SMAD2 occupancy across the LAMC2 gene region in control and TGF-β1-treated cells through Cut&Tag analysis. (G) The graphical abstract of LAMC2-mediated positive feedback loop in the TGF-β pathway in GBC. One-way ANOVA was calculated for statistical significance. Values are expressed as mean ± SD. * p < 0.05, **p < 0.01, ***p < 0.001, ns means not significant. n = 3 biologically independent samples TGF-β regulates expression of LAMC2 via SMAD2. (A) The protein level of LAMC2 under TGF-β1 (20 ng/ml) stimulation in HCC453 and GBC-SD cells. (B) The mRNA level of LAMC2 under TGF-β1(20 ng/ml) stimulation in HCC453 and GBC-SD. (C) The expression of LAMC2 under TGF-β1 stimulation in response to treatment with actinomycin D (1 µM) by qRT-PCR. (D) The protein level of LAMC2 under TGF-β1 stimulation with TGF-β inhibitor vactosertib (1 µM). (E) The protein level of LAMC2 under TGF-β1 stimulation with SMAD2 knockdown in GBC-SD. (F) The SMAD2 occupancy across the LAMC2 gene region in control and TGF-β1-treated cells through Cut&Tag analysis. (G) The graphical abstract of LAMC2-mediated positive feedback loop in the TGF-β pathway in GBC. One-way ANOVA was calculated for statistical significance. Values are expressed as mean ± SD. * p < 0.05, **p < 0.01, ***p < 0.001, ns means not significant. n = 3 biologically independent samples Discussion The curative-intent therapy for GBC is radical resection, but only 10–25% of patients are eligible for surgery [19]. Most patients are in the advanced stage at the time of diagnosis and need nonsurgical treatments such as chemotherapy and radiotherapy. Unfortunately, the prognosis for these patients remains poor. Therefore, substantial effort has been devoted to genomic- and immuno-profiling with the help of advanced technology [20, 21]. Targets such as human epidermal growth factor receptor 2 (HER2), growth factor receptor tyrosine kinases (RTKs), and PD-1/PD-L1 are now emerging as viable therapeutic options [22]. Based on the molecular signature, targeted therapy and immunotherapy have recently shown promising potential for improving GBC patient survival in clinical trials [23, 24]. The emergence of multi-omics approaches, including next-generation sequencing (NGS), proteomics, and transcriptomics, profoundly reveals the molecular characteristics, disease heterogeneity, and progression of GBC [21, 25, 26]. In this context, we integrated proteomics and RNA-sequencing assays to identify differentially expressed proteins involved in GBC progression. Through experimental validation, we found that LAMC2 was significantly upregulated in GBC compared with normal gallbladder tissues. Moreover, the upregulation of LAMC2 was correlated with poor overall survival and independently predicted poor prognosis in GBC patients. Thus, LAMC2 has significant potential as both a prognostic biomarker and a therapeutic target for GBC. The extracellular matrix (ECM) is essential for various biological functions to maintain tissue architecture, support cell adhesion, and also act as signaling molecules [4]. Disruption of ECM dynamics is a tumor signature and contributes to cancer development and progression [4, 7]. Laminin 332 (LM332), a basement membrane component, plays an important role in tumorigenesis, and its dysregulated expression could cause the epithelial cells to lose polarity and acquire metastatic ability [27]. LM332 consists of three subunits, each contributing uniquely to tumor progression [28]. Among these subunits, LAMC2 is an exclusive and attractive isoform. Our multiomics analysis showed that LAMC2 was specifically upregulated in GBC tissue. LAMC2 deposition has been observed in some metastatic cancers, where it correlated with invasion and metastasis [29]. The biological behavior of GBC is characterized by its tendency to invade and metastasize to distant sites such as the lymph nodes [30], liver, and other organs [31]. In line with this, our data revealed that LAMC2 expression was positively associated with the TNM stage in our clinical cohort and enhanced in advanced GBC patients from GSE202479 dataset. Additionally, LAMC2 promoted cell migration and invasion in vitro and facilitated liver metastasis in mouse models. Furthermore, LAMC2 has been reported to endow pancreatic cancer with increased stemness and high metastatic capacity [32]. Consistent with this, we found that knockdown of LAMC2 suppressed tumor spheroid formation and downregulated stemness-related markers. Meanwhile, GBC organoid growth was also inhibited upon LAMC2 depletion. These results collectively indicate that LAMC2 drives malignant progression in GBC. Epithelial-mesenchymal transition (EMT) is a biological process in which epithelial cells lose their polarity and acquire a mesenchymal phenotype. This transition is orchestrated by a set of EMT-related transcription factors (EMT-TFs), including ZEB family, SNAIL and SLUG [33]. These regulators repress epithelial markers such as E-cadherin, while inducing mesenchymal markers like N-cadherin and vimentin [34]. This process enhanced aggressiveness and metastatic propensity of tumor cells. EMT also promotes the acquisition of cancer stem cell traits, further enhancing metastatic capability and compromising therapeutic efficacy [35]. The EMT process is tightly regulated by multiple signaling pathways, among which the TGF-β signaling plays a crucial role [36]. TGF-β signaling elicits both structural and functional cellular changes through SMAD-dependent or SMAD-independent pathways to regulate EMT [37, 38]. Our findings indicate that LAMC2 expression enhances TGF-β1-induced activation of the TGF-β signaling pathway and partially promotes the expression of EMT-related molecules. Importantly, we identified an interaction between LAMC2 and TGF-βRII, the primary receptor responsible for TGF-β1 ligand binding and propagation of downstream signaling [39]. Activation of TGF-βRII promotes SMAD phosphorylation and nuclear translocation, enabling SMAD complexes to directly or cooperatively activate transcription of EMT-related genes alongside EMT-TFs [40–42]. Furthermore, we demonstrated that SMAD2 activation upregulates LAMC2 transcription, establishing a positive feedback loop that amplifies TGF-β signaling output. This mechanism is consistent with earlier observations linking LAMC2 upregulation to TGF-β1 stimulation [9, 32]. Functionally, LAMC2 enhanced cellular invasion and migration in vitro, and these effects are attenuated upon inhibition of the TGF-β pathway, suggesting that LAMC2’s function is closely linked to the TGF-β pathway. Taken together, our findings suggest LAMC2 could reinforce TGF-β signaling and augment TGF-β-induced EMT, thereby contributing to increased metastatic potential. Our findings demonstrate that LAMC2 is significantly overexpressed in GBC tissues (relative to normal GB tissues) and is independently associated with poor overall survival in GBC patients, supporting its potential as a prognostic biomarker for risk stratification of GBC patients. More importantly, given the regulatory role of LAMC2 in the malignant progression of GBC cells, the development of LAMC2-targeted therapies represents a compelling avenue for further research. Notably, a study reported that the XPO1 inhibitor eltanexor can effectively target the miR-193b/LAMC2/KRAS axis to suppress pancreatic cancer progression [43], providing the feasibility for LAMC2-targeted therapies. In our study, we identify an interaction between LAMC2 and TGF-βRII that modulates TGF-β signal activation and downstream EMT marker expression. This LAMC2-TGF-βRII interaction interface represents a highly specific therapeutic target, for example, small-molecule inhibitors or neutralizing antibodies designed to block this interaction could directly abrogate LAMC2-mediated pro-metastatic signaling, with minimal off-target effects compared to non-specific pathway inhibition. Moreover, our data reveal that TGF-β/SMAD2 signaling directly regulates LAMC2 transcription, forming a positive feedback loop that amplifies TGF-β pathway activity. Our data showed TGF-β receptor inhibitor vactosertib—which is currently under clinical investigation—effectively suppressed LAMC2 expression and inhibited the invasive capacity of LAMC2-overexpressing GBC cells [44]. These results suggest that co-targeting LAMC2 and TGF-β signaling may enhance treatment efficacy in advanced GBC. In summary, our findings show that LAMC2 drives malignant progression and predicts poor survival in GBC. Notably, LAMC2 upregulation, regulated by the TGF-β/SMAD2 pathway, amplifies TGF-β signaling and the expression of EMT-related molecules by binding to TGF-βRII. Supplementary Information Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3